Tesamorelin for Health & Longevity

Evidence Review created on 08/07/2026 using AI4L / Opus 5

Also known as: Egrifta, Egrifta SV, Egrifta WR, TH9507, Tesamorelin Acetate

Motivation

Tesamorelin is a laboratory-made copy of the natural signal the brain uses to tell the pituitary gland to release growth hormone. Rather than injecting growth hormone itself, it prompts the body to make its own in its natural pulsing rhythm. Interest in it centers on one specific effect: it shrinks the deep fat packed around the abdominal organs, the fat most closely tied to blood-sugar and heart problems, while largely sparing the fat just under the skin.

It was developed for a narrow purpose, treating the abdominal fat build-up that can accompany long-term treatment for the virus that attacks the immune system, and it remains approved only for that use. Its appeal beyond that setting rests on a simple observation: deep abdominal fat and the liver fat that travels with it both accumulate with age, while the body’s own growth hormone output falls over the same decades.

This review examines how tesamorelin works, what it has and has not been shown to do, what risks and open questions accompany raising growth hormone signaling long term, how it is used in practice, and what can be measured to track its effects.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Tesamorelin

A dedicated encyclopedia entry covering the compound’s structure as a stabilized 44-amino-acid growth hormone-releasing hormone analog, its approval history, its trial record, and its off-label use. It is the most complete single-page reference that also addresses non-approved uses.

Examine

No Examine article exists for tesamorelin.

Tesamorelin is a prescription injectable medication, and Examine.com restricts its coverage to dietary supplements and nutrition topics; it does not typically cover prescription medications.

ConsumerLab

No ConsumerLab article exists for tesamorelin.

Tesamorelin is a prescription injectable medication rather than a consumer supplement, and ConsumerLab’s independent testing program covers vitamins, supplements, and foods; it does not typically cover prescription medications.

Systematic Reviews

The systematic reviews and meta-analyses below pool the randomized evidence on tesamorelin, all of it drawn from trials in people with HIV.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials - Badran et al., 2026

The most recent and most complete pooling of the randomized evidence on tesamorelin as an analog of growth hormone-releasing hormone (GHRH, the hypothalamic signal that instructs the pituitary gland to secrete growth hormone), covering five randomized controlled trials (RCTs, studies in which participants are assigned by chance to treatment or placebo) with formal risk-of-bias and certainty grading. It is the best single source for effect sizes on deep abdominal fat, liver fat, lean mass, and adverse events.
Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis - Ditta et al., 2026

An independent 2026 pooling of four trials in 909 participants that reaches the same body-composition conclusions but is notably more cautious, flagging substantial between-trial inconsistency for the deep abdominal fat estimate and a higher discontinuation rate on treatment. Reading it alongside Badran et al. shows how much the pooled fat estimate moves with trial selection.
Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials - Sivakumar et al., 2011

The earliest systematic review to place tesamorelin in context against the wider growth hormone axis, pooling ten trials of growth hormone, growth hormone-releasing hormone, and insulin-like growth factor 1 in 1,511 patients. Its subgroup analysis is the clearest available comparison of what the releasing-hormone approach gains and gives up relative to growth hormone itself.

Mechanism of Action

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH). Structurally it is the full 44-amino-acid hormone with a trans-3-hexenoyl group attached to the N-terminus. That single modification blocks cleavage by dipeptidyl peptidase-4 (DPP-4, an enzyme in blood that rapidly chops up small peptides), which is what makes the molecule survive long enough to be dosed once daily by injection, unlike native GHRH.

Upstream, not downstream, stimulation: Tesamorelin binds the GHRH receptor on pituitary somatotroph cells and amplifies the body’s own growth hormone (GH) pulses. Because the pituitary remains under the control of somatostatin (the opposing hypothalamic brake) and of negative feedback from insulin-like growth factor 1 (IGF-1, the liver-derived hormone through which most GH effects are mediated), the resulting GH profile stays pulsatile and self-limiting. This is the central mechanistic argument for a releasing hormone over injected GH, which produces continuous, unregulated exposure.
Selective loss of deep abdominal fat: Visceral adipose tissue (VAT, the fat packed around the abdominal organs) carries a higher density of GH receptors than fat under the skin. Raised GH stimulates hormone-sensitive lipase (the enzyme that breaks stored fat down for release), suppresses lipoprotein lipase (the enzyme that draws circulating fat into fat cells for storage), and inhibits 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1, the enzyme that regenerates active cortisol inside fat tissue). The net result is preferential breakdown of visceral fat with little change in subcutaneous fat.
Liver fat and hepatic gene expression: Reduced visceral fat lowers the flow of free fatty acids to the liver, and GH additionally suppresses hepatic de novo lipogenesis (the liver’s manufacture of new fat from carbohydrate). Transcriptomic work on liver biopsies from treated participants found downregulation of pathways governing fat synthesis and inflammation, supporting a direct hepatic action rather than a purely secondary one.
Receptor selectivity: Tesamorelin acts only at the GHRH receptor. It does not activate the growth hormone secretagogue receptor GHS-R1a (the ghrelin receptor targeted by ipamorelin, GHRP-2 (growth hormone-releasing peptide 2), and ibutamoren), so it does not raise cortisol or prolactin and does not stimulate appetite. This is a meaningful practical difference from the peptides it is most often stacked with.
Pharmacological properties: After subcutaneous injection the elimination half-life is roughly 26 minutes in healthy adults and roughly 38 minutes in people with HIV, and absolute bioavailability is low, under about 4%. It is a peptide, so it is cleared by ubiquitous peptidases into amino acids and small fragments rather than by liver enzymes; it is not a substrate of the cytochrome P450 system, and dedicated interaction studies found minimal effect on CYP3A4 (cytochrome P450 3A4, the liver enzyme that metabolizes a large share of prescription drugs). Distribution is effectively confined to plasma and the anterior pituitary; the downstream signal, not the drug, is what reaches peripheral tissue.
Competing mechanistic accounts: The favorable account holds that restoring youthful, pulsatile GH output corrects an age-related deficit and remodels the most metabolically harmful fat depot. The opposing account holds that the visceral fat loss is simply a lipolytic effect of any sustained GH elevation, achievable with GH itself, and that the accompanying rise in IGF-1 is the mechanistically relevant exposure. That second reading matters for longevity specifically, because reduced GH/IGF-1 signaling, not increased signaling, is the direction associated with extended lifespan in model organisms and with exceptional longevity in some human cohorts. Both accounts are consistent with the same trial data; they diverge on which variable to optimize.

Historical Context & Evolution

Original intended use: Tesamorelin was developed by Theratechnologies as TH9507, a stabilized GHRH analog intended to correct the blunted GH secretion and abdominal fat accumulation seen in people on long-term antiretroviral therapy (ART, the drug combinations that suppress HIV). A dose-ranging trial in 2005 and two phase 3 programs led to United States approval in 2010 under the brand name Egrifta, with the indication restricted to reduction of excess abdominal fat in that population.
What the original research actually found: The pivotal 26-week trial reported a selective reduction in deep abdominal fat with no significant loss of fat under the skin, alongside improved triglycerides and improved patient-rated body image. The pooled phase 3 analysis added that the effect was maintained through 52 weeks in participants who stayed on treatment, and that it reversed in those switched to placebo. Glucose parameters showed a small, early rise that did not persist as a clinically meaningful difference at 26 or 52 weeks. These are the findings themselves, not a later summary of them, and they set both the promise and the ceiling of the compound.
Why it moved into health optimization: Three observations pulled it outside its licensed indication. First, deep abdominal fat accumulates with age in people without any viral infection and predicts cardiometabolic disease independently of body weight. Second, the same investigators showed reductions in liver fat, and later in markers of liver scarring, in a population with fatty liver disease. Third, a university-run trial in older adults without HIV, using 1 mg daily for 20 weeks, reported a favorable effect on thinking, particularly executive function. Together these suggested the mechanism was not specific to virus-associated fat redistribution.
How opinion has shifted, and why: Early enthusiasm for growth hormone as a longevity agent in the 1990s gave way to a more restrictive view as trials showed body-composition changes without functional gains and with side effects. Rather than treating that as a settled verdict, the GHRH-analog literature reframed the question: whether the problem was the hormone or the unphysiological way it was delivered. Newer evidence cuts both ways. Liver fat and body-composition benefits have been reproduced, including in participants on modern integrase inhibitor regimens (the drug class that now forms the backbone of first-line HIV treatment). Against that, a 2025 randomized trial in people with HIV and abdominal obesity found no significant between-group cognitive benefit, weakening the extrapolation from the 2012 trial. The current position is not that the longevity case was disproven, but that it remains untested where it matters: no trial has measured hard clinical outcomes, and the longevity biology of chronically raised IGF-1 argues in the opposite direction from the body-composition data.
Formulation evolution: The product itself has changed three times, from the original two-vial Egrifta at 2 mg daily, to Egrifta SV at 2 mg daily in a single vial, to Egrifta WR at 1.28 mg daily, approved in 2025, which is reconstituted weekly, stored at room temperature, and injected in less than half the volume. The dose numbers differ because the formulations differ in delivery, not because the target exposure changed.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Deep Abdominal (Visceral) Fat

This is the effect tesamorelin was approved for and the only one supported by multiple large placebo-controlled trials plus two independent 2026 meta-analyses. Raised GH acts preferentially on visceral fat because that depot is richer in GH receptors, producing fat loss around the organs with essentially no loss of fat under the skin, a dissociation no diet or exercise protocol reliably achieves. The evidence base is five randomized trials, but every one of them enrolled people on antiretroviral therapy, and the pivotal trials were designed and funded by the manufacturer, Theratechnologies, whose commercial interest in a positive visceral fat result is direct. Response is not universal: roughly a third of participants fail to reach the 8% reduction threshold used to define response.

Magnitude: Pooled mean difference of -27.7 cm² of visceral fat area versus placebo (95% confidence interval, or CI, the range within which the true value most likely lies: -38.4 to -17.1), corresponding to a within-group fall of about -15% from baseline at 26 weeks against a roughly +5% rise on placebo, and about -17.5% sustained at 52 weeks in those who continued; waist circumference falls by about 1.6 cm.

Reduction of Liver Fat

Tesamorelin lowers hepatic fat both indirectly, by cutting the supply of fatty acids released from visceral fat, and directly, by suppressing the liver’s own fat synthesis. The strongest evidence is a 12-month double-blind trial in people with HIV and non-alcoholic fatty liver disease (NAFLD, fat accumulation in the liver not caused by alcohol, now often called metabolic dysfunction-associated steatotic liver disease), plus a confirmatory subgroup analysis in participants on modern integrase inhibitor regimens. Liver-biopsy transcriptomics from the same trial showed coordinated downregulation of fat-synthesis and inflammation pathways, which is unusual mechanistic corroboration for a body-composition drug. This trial was investigator-initiated and publicly funded, which partly offsets the sponsorship concern attached to the phase 3 program.

Magnitude: Absolute reduction in hepatic fat fraction of -4.1% versus placebo (95% CI -7.6 to -0.7), a -37% relative reduction; 35% of treated participants versus 4% on placebo fell below the 5% threshold that defines fatty liver.

Increase in Lean Body Mass

Raising GH and IGF-1 increases nitrogen retention and lean tissue, and this shows up consistently across the randomized trials as a gain in lean mass alongside the fat loss. The effect is modest in absolute terms and, importantly, has never been shown to translate into greater strength or physical performance, because no completed trial measured those endpoints. A secondary imaging analysis in treatment responders also found increased trunk muscle area and higher muscle density, the latter indicating less fat infiltration into muscle, which is a marker of muscle quality relevant to aging. Whether this matters functionally is exactly the question the ongoing TRIUMPH trial was designed to answer.

Magnitude: Pooled mean difference of +1.42 kg lean body mass versus placebo (95% CI +1.13 to +1.71); trunk muscle density increased by roughly 1.4 to 4.9 Hounsfield units in responders.

Restoration of Insulin-Like Growth Factor 1 to the Upper Physiological Range

Tesamorelin reliably and substantially raises IGF-1, which is the pharmacodynamic proof that the drug is working and the variable clinicians titrate against. In the pooled phase 3 data IGF-1 rose steeply in the treated arm and not at all on placebo, and in the trial of older adults without HIV it roughly doubled while remaining inside the normal range. For a reader whose IGF-1 sits low for their age, this is the most direct way to move it. Whether that is desirable is a separate question addressed under Potential Risks; the reliability of the effect itself is not in doubt.

Magnitude: Mean IGF-1 increase of about +108 ng/mL versus -7 ng/mL on placebo in pooled phase 3 data; roughly +117% in older adults dosed at 1 mg daily for 20 weeks.

Medium 🟩 🟩

Improvement in Blood Lipids

Visceral fat drives hepatic overproduction of triglyceride-rich lipoproteins, so removing it improves the lipid panel. Randomized data show meaningful triglyceride reductions and a better ratio of total cholesterol to HDL (high-density lipoprotein, the particle that carries cholesterol away from the artery wall), and the 2026 pooled analysis confirmed a small but statistically significant fall in total cholesterol. The grade is Medium rather than High because the effects are modest, are not seen uniformly across every lipid fraction, and no trial has measured apolipoprotein B (the particle-count measure that best tracks cardiovascular risk). The improvement also appears confined to participants who actually lose visceral fat.

Magnitude: Triglycerides fell by about 37 mg/dL versus a 6 mg/dL rise on placebo, a within-group fall of about -12% from baseline; total cholesterol fell by a pooled -0.16 mmol/L (95% CI -0.27 to -0.06).

Slowing of Liver Fibrosis Progression

In the 12-month liver trial, paired biopsies showed that fewer treated participants progressed in fibrosis stage (the accumulation of scar tissue that determines long-term liver prognosis) than participants on placebo. This is the only outcome in the entire tesamorelin literature that touches disease progression rather than an imaging or laboratory surrogate, which makes it disproportionately important. It is graded Medium rather than High because it was a secondary endpoint in a single trial of 61 participants, biopsy sampling is subject to error, and no replication exists.

Magnitude: Fibrosis progression in 10.5% of treated participants versus 37.5% on placebo over 12 months.

Improvement in Muscle Quality and Reduction of Fat Infiltration in Muscle

Beyond the increase in lean mass, imaging shows that treated responders gain muscle density, meaning less fat is deposited inside and between muscle fibers. Intramuscular fat infiltration rises with age and is more tightly linked to weakness and frailty than muscle size alone, so this is mechanistically the more interesting finding of the two. The evidence is a pre-specified secondary analysis of two randomized trials restricted to responders, which limits how far it generalizes, and no functional testing accompanied it.

Magnitude: Increases of 0.44 to 1.08 cm² in lean muscle area across four trunk muscle groups, with density gains of 1.4 to 4.9 Hounsfield units.

Improvement in Self-Rated Body Composition and Body Image

Trial participants and their physicians independently rated abdominal profile as improved, and belly-appearance distress fell significantly. This matters more than it may appear: it is the only patient-reported outcome measured across the phase 3 program, and adherence to any injectable regimen tracks perceived benefit. The grade reflects that these are unblinded-to-appearance subjective ratings in a population selected for visible fat redistribution, which does not transfer cleanly to a reader with ordinary age-related abdominal fat.

Magnitude: Belly-appearance distress improved versus placebo at p = 0.002 (p is the probability that a difference this large would arise by chance alone; values below 0.05 are conventionally called significant); patient and physician ratings of belly profile improved at p = 0.003 and p < 0.001 respectively.

Low 🟩

Cognitive Performance ⚠️ Conflicted

The strongest positive signal comes from a 20-week randomized trial of 152 adults aged 55 to 87, both healthy and with mild cognitive impairment (a stage of memory or thinking decline that is measurable but not yet dementia), which found a favorable overall cognitive effect driven mainly by executive function, with a non-significant trend in verbal memory. A companion imaging study found treatment-related changes in brain GABA (gamma-aminobutyric acid, the main calming neurotransmitter) levels, offering a plausible mechanism. Against this, a 2025 randomized phase 2 trial in 73 people with HIV and abdominal obesity found no significant difference between groups despite achieving the expected waist reduction, and IGF-1 changes did not correlate with cognitive change. The conflict is best explained by population and design: the positive trial was placebo-controlled in a general older population at a lower dose, while the null trial was open-label against standard care, underpowered, and in a different population.

Magnitude: Favorable overall cognitive effect at p = 0.03 in intention-to-treat analysis (every randomized participant counted, including those who stopped early) and p = 0.005 for executive function in the 2012 trial; between-group difference p = 0.673 in the 2025 trial.

Reduction in Inflammatory Markers

Visceral fat is a source of inflammatory signaling, so removing it should lower systemic inflammation. Analyses of the phase 3 dataset found reductions in tissue plasminogen activator and, among participants who actually lost visceral fat, in C-reactive protein (CRP, a general blood marker of inflammation). The grade is Low because these were post-hoc analyses of secondary markers, the effect appeared only in responders, and inflammatory markers were not a pre-specified endpoint in any trial.

Magnitude: Not quantified in available studies.

Improvement in Mitochondrial Function

In a 12-month placebo-controlled trial in 39 adults with obesity and reduced GH secretion, increases in IGF-1 correlated with faster phosphocreatine recovery after exercise, a magnetic resonance measure of how quickly muscle regenerates its energy stores and a standard proxy for mitochondrial capacity. The association strengthened when the analysis was restricted to treated participants and survived adjustment for body composition and insulin sensitivity. It is graded Low because the finding is a correlation within a small trial rather than a between-group treatment effect, and it has not been replicated.

Magnitude: Correlation of r = 0.56 (r is the correlation coefficient, running from 0 for no relationship to 1 for a perfect one; p = 0.01) overall and r = 0.71 (p = 0.03) within the treated group between IGF-1 rise and phosphocreatine recovery.

Speculative 🟨

Improved Sleep Depth

GHRH administration promotes slow-wave sleep (the deepest, most restorative stage of non-dreaming sleep) in human sleep-laboratory studies of the native hormone, and bedtime dosing is the near-universal practice in off-label use partly for this reason. No controlled trial has measured sleep architecture or subjective sleep quality on tesamorelin specifically; a planned trial in service members with traumatic brain injury and insomnia was withdrawn before enrolling anyone. The basis for this item is therefore mechanistic plus anecdotal report only.

Accelerated Peripheral Nerve Regeneration

Animal work shows GH and IGF-1 support axon regrowth and limit the muscle wasting that follows denervation, which motivated an ongoing randomized trial in surgically repaired ulnar nerve lacerations. No human results exist yet. The basis is preclinical data and a trial in progress, not controlled human evidence.

Preservation of Lean Mass Alongside Incretin-Based Weight Loss

Because GLP-1 receptor agonists (glucagon-like peptide-1 receptor agonists, the incretin drugs used for weight loss) cause substantial lean-mass loss along with fat loss, a mechanistically obvious pairing is to add an agent that increases lean mass. No trial has tested the combination, and the interaction of the two on blood sugar is unstudied. The basis for this item is mechanistic reasoning and clinic-level practice reports only.

Skin Quality and Recovery from Training

Reports from off-label users describe improved skin texture and faster recovery between training sessions, and GH does drive collagen turnover. No controlled study has measured either endpoint with tesamorelin, and the parallel literature on growth hormone for tissue repair in non-deficient adults is largely negative. The basis is anecdotal report supported by a mechanism whose clinical translation has repeatedly failed.

Benefit-Modifying Factors

Baseline visceral fat and waist circumference: The single strongest predictor of response is having a large amount of the fat the drug removes. Analyses of phase 3 predictors found that greater baseline visceral fat area and larger waist circumference predicted greater absolute reduction, while participants with modest baseline visceral fat had little room to respond. A reader whose abdominal fat is mostly subcutaneous should expect very little.
Baseline IGF-1 and growth hormone status: Benefit tracks the size of the IGF-1 increase achieved. Those starting with low-for-age IGF-1 and blunted GH pulsatility have the most headroom; those already in the upper part of the reference range gain less and hit the safety ceiling sooner. In the mitochondrial trial, participants were specifically selected for reduced GH secretion, and the benefit correlated with the IGF-1 rise rather than with dose.
Sex and estrogen exposure: Oral estrogen passes through the liver first and blunts hepatic IGF-1 generation, so women on oral contraceptives or oral estradiol can achieve a smaller IGF-1 response at the same dose than men or than women using transdermal estrogen. The phase 3 population was roughly 87% male, so sex-specific effect estimates are weak. Trials in nerve regeneration explicitly exclude oral contraceptive users for this reason.
Growth hormone receptor genotype: The exon 3-deleted variant of the growth hormone receptor gene (d3-GHR, a common deletion that produces a receptor with enhanced signaling) is associated with greater responsiveness to GH-axis stimulation in several endocrine settings. Variants in the GHRH receptor gene itself (GHRHR, the gene encoding the receptor tesamorelin binds) can blunt response. Neither has been tested prospectively in tesamorelin trials, so this is a plausible rather than established modifier.
Age: Benefit has been demonstrated across the adult range, including in trials enrolling participants up to 87 years old, and the age-related decline in GH pulse amplitude means older readers generally start further from the ceiling. Counterbalancing this, fluid retention, joint symptoms, and carpal-tunnel-type complaints are more common with age, and the pituitary response to GHRH itself declines, so the same dose can produce a smaller IGF-1 rise in the oldest readers.
Pre-existing metabolic and liver conditions: Fatty liver disease amplifies the measurable benefit because there is more hepatic fat to remove. Established type 2 diabetes works in the opposite direction, both because GH opposes insulin action and because the efficacy trials excluded participants with poor glycaemic control; a short dedicated safety trial in stable type 2 diabetes found no loss of glycaemic control, but no efficacy trial has measured the benefit-to-risk balance in that group.
Adherence and injection technique: The effect requires daily dosing; the visceral fat benefit at 26 weeks was substantially attenuated in participants with poor adherence, and rotating injection sites matters because repeated injection into the same area produces local reactions that drive discontinuation.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection Site Reactions

Local erythema (redness), pruritus (itching), pain, bruising, and urticaria (hives) at the injection site are the most frequent adverse events and the most common reason for discontinuation. The mechanism is a combination of the peptide itself and the mannitol excipient in the formulation. They are graded High because they appeared consistently across every randomized trial and both meta-analyses, and they were the dominant adverse event in the 12-month liver trial. They are self-limiting, respond to site rotation, and no case in the trial program was judged serious.

Magnitude: Injection site erythema in 8.5% of treated participants versus 2.7% on placebo over 26 weeks, with any injection site reaction reported by roughly one in four treated participants.

Joint and Muscle Pain

Arthralgia (joint pain), myalgia (muscle pain), and pain in the extremities are classic GH-axis side effects, driven by fluid shifts into connective tissue and by direct effects on collagen turnover. They are among the few adverse events reproduced in both 2026 meta-analyses as well as the original phase 3 program. Severity is usually mild to moderate, onset is within the first weeks, and symptoms often attenuate with continued dosing or resolve on dose reduction; they are the same complaints that limited the older growth hormone trials in healthy older adults.

Magnitude: Arthralgia in 13.3% of treated participants versus 11.7% on placebo, myalgia in 5.5% versus 1.8%, and pain in extremity in 6.1% versus 4.5% over 26 weeks.

Fluid Retention and Peripheral Edema

Growth hormone promotes sodium and water retention through the renin-angiotensin-aldosterone system (RAAS, the hormone cascade that regulates blood pressure and fluid balance) and through direct renal tubular effects. The result is peripheral edema (swelling of the ankles, feet, and hands), sometimes with a sensation of tightness or stiffness. It is dose-related and reversible on stopping. This is the mechanism that connects several of the other listed risks, including carpal tunnel symptoms and any worsening of sleep-disordered breathing.

Magnitude: Peripheral edema in 6.1% of treated participants versus 2.2% on placebo over 26 weeks.

Early Rise in Blood Glucose ⚠️ Conflicted

GH directly antagonizes insulin action in muscle and liver, and an early rise in fasting glucose is reproducibly observed. In a randomized trial the treated group’s fasting glucose rose by 9 mg/dL at two weeks versus 2 mg/dL on placebo, a significant difference. The conflict is about persistence: the same trial found no significant difference at six months, the 12-month liver trial found no difference in fasting glucose or HbA1c (glycated haemoglobin, a three-month average of blood sugar), the pooled phase 3 analysis reported no clinically meaningful glucose changes at 26 or 52 weeks, and the 2026 meta-analysis concluded there was no perturbation of glucose. Against those, the prescribing information carries a warning on glucose intolerance and reports a higher incidence of new diabetes on treatment. The efficacy trials excluded participants with HbA1c above 8%, though a dedicated 12-week randomized placebo-controlled trial in 53 people with stable type 2 diabetes found no change in insulin response, fasting glucose, HbA1c, or overall diabetes control at either 1 or 2 mg daily, so the group usually assumed to be most at risk is not wholly unstudied.

Magnitude: Fasting glucose treatment effect of +7 mg/dL (95% CI +1 to +14) at two weeks, resolving to a non-significant +2 mg/dL at six months; labeled incidence of new diabetes 4.5% on treatment versus 1.3% on placebo at 26 weeks.

Anti-Tesamorelin Antibody Formation

About half of treated participants develop immunoglobulin G antibodies against tesamorelin within 26 weeks, a consequence of injecting a modified peptide hormone. Roughly 60% of those antibodies also cross-react with native GHRH. This is graded High because the frequency is well characterized across the phase 3 program, not because the consequence is severe: antibody-positive participants showed no attenuation of the IGF-1 response and no loss of visceral fat benefit, and no antibody-associated hypersensitivity syndrome emerged. The relevant unknown is what a decade of antibody exposure does, since the antibody data stop at 52 weeks and the longest tesamorelin trials ran only 18 months.

Magnitude: Anti-tesamorelin immunoglobulin G antibodies detected in approximately 50% of treated participants by week 26, with no measurable loss of treatment effect.

Medium 🟥 🟥

Loss of Benefit After Discontinuation

Visceral fat returns after treatment stops. In the phase 3 extension, participants rerandomized from tesamorelin to placebo lost the reduction they had gained, while those who continued maintained it through 52 weeks. This makes tesamorelin a maintenance therapy rather than a course of treatment, which converts an intermittent cost and injection burden into an indefinite one and means any long-term risk accrues continuously. It is graded Medium because it is documented in one extension design rather than across multiple trials.

Magnitude: Visceral fat reduction of -17.5% maintained at 52 weeks in continuers versus regression toward baseline in those switched to placebo.

Paresthesia, Hypoesthesia, and Carpal Tunnel Syndrome

Paresthesia (tingling), hypoesthesia (reduced sensation or numbness), and carpal tunnel syndrome (compression of the median nerve where it passes through the wrist) are recognized GH-axis effects mediated by soft-tissue fluid retention in confined anatomical spaces. They appear in the prescribing information and in trial adverse-event tables at low single-digit rates, are usually mild, and resolve on dose reduction or discontinuation. The grade reflects consistent but low-frequency reporting across trials rather than a strong quantified signal, and the same symptoms are far more prominent with injected growth hormone than with releasing-hormone analogs.

Magnitude: Paresthesia and hypoesthesia each reported in roughly 3% to 5% of treated participants; carpal tunnel syndrome reported at under 2%.

Hypersensitivity Reactions

Rash, pruritus, and urticaria occurring beyond the injection site were reported in a small minority of trial participants, and hypersensitivity to tesamorelin or to the mannitol excipient is a labeled contraindication. Reactions were mild in the trial program with no anaphylaxis reported, but the postmarketing population is small enough that rare severe events would be hard to detect. The grade reflects clear trial documentation of a low-frequency, generally mild event.

Magnitude: Hypersensitivity reactions in approximately 4% of treated participants across the clinical trial program; anti-tesamorelin antibodies were detectable in 85% of that subgroup.

Gastrointestinal Effects

Vomiting and dyspepsia (indigestion) appear in the labeled adverse reaction tables at low frequency, likely reflecting general GH-axis effects rather than a specific mechanism; nausea is not among the reactions the label reports as more frequent than placebo. They are usually transient and rarely limit treatment. Notably, and unlike ghrelin-receptor peptides, tesamorelin does not stimulate appetite, so weight gain from increased food intake is not part of its profile.

Magnitude: Vomiting in 3% of treated participants versus 0% on placebo and dyspepsia in 2% versus 1% over 26 weeks.

Higher Discontinuation Rate on Treatment

The 2026 systematic review found more participants stopped treatment on tesamorelin than on placebo, driven mainly by local reactions and joint symptoms rather than by serious events. This is a practical risk distinct from any single side effect, because the benefit depends entirely on staying on the drug. It is graded Medium because the pooled estimate did not reach statistical significance and rests on four trials.

Magnitude: Pooled risk ratio for discontinuation 2.25 (a risk ratio is how many times more likely the event is on treatment than on placebo; 95% CI 0.98 to 5.17, p = 0.06).

Low 🟥

Theoretical Promotion of Occult Neoplasia

IGF-1 is mitogenic and antiapoptotic, meaning it encourages cell division and discourages programmed cell death, so raising it could in principle accelerate growth of an existing undetected tumor. This drives the absolute contraindication in active malignancy and the requirement for age-appropriate cancer screening before starting. No excess of malignancy appeared in the trial program, but the longest exposure studied is 18 months, which is far too short to detect a cancer signal. The grade is Low because it rests on mechanism and epidemiology of IGF-1 rather than on any observed trial signal.

Magnitude: Not quantified in available studies.

Worsening of Diabetic Retinopathy

Growth hormone has historically been implicated in proliferative retinopathy (abnormal blood vessel growth in the retina that can threaten vision), which is why the manufacturer ran a dedicated postmarketing retinopathy study. That study was terminated early without establishing a signal. The concern remains theoretically live for readers with existing retinopathy and poorly controlled blood sugar, which is precisely the group trials excluded.

Magnitude: Not quantified in available studies.

Worsening of Sleep-Disordered Breathing

Fluid retention and soft-tissue expansion in the upper airway are plausible aggravators of obstructive sleep apnea (repeated airway collapse during sleep), and a trial designed to test this was withdrawn before enrolling participants. Weighed against it, visceral and neck fat reduction should improve airway mechanics over time, so the net direction is genuinely unclear. The grade reflects an absence of direct evidence rather than reassurance.

Magnitude: Not quantified in available studies.

Suppression of Circulating Cortisol Through 11β-HSD1 Inhibition

By inhibiting the enzyme that regenerates active cortisol inside tissue, GH lowers effective cortisol exposure. This is beneficial in most contexts but is clinically relevant for anyone on cortisol replacement, who may become under-replaced. It is graded Low because it is an established pharmacological effect rather than a frequently reported adverse event, and it is manageable by dose adjustment.

Magnitude: Not quantified in available studies.

Speculative 🟨

Unfavorable Long-Term Effect on Longevity from Sustained IGF-1 Elevation

This is the most consequential unknown for a longevity-oriented reader, and it runs opposite to every benefit above. Reduced GH/IGF-1 signaling extends lifespan across yeast, worms, flies, and mice; growth hormone receptor-deficient mice are among the longest-lived strains known; and humans with inherited growth hormone receptor deficiency show low rates of cancer and diabetes. Several human cohorts link lower IGF-1 in later life with survival advantage, though the association is not uniform and some cohorts find a U-shaped relationship. Tesamorelin moves IGF-1 in the direction associated with shorter, not longer, life in these models. No trial has run long enough to test this, and the basis for this item is comparative biology and observational epidemiology, not controlled human data.

Acromegaly-Like Soft Tissue Changes with Supraphysiological Off-Label Dosing

At approved doses IGF-1 stays within the physiological range and no acromegalic features (coarsening of facial features, enlargement of hands and feet from chronic growth hormone excess) have been reported. The concern applies specifically to off-label use at higher doses or stacked with ghrelin-receptor peptides, where combined GH release could push IGF-1 above the reference range for extended periods. The basis is mechanistic extrapolation from acromegaly and isolated user reports, with no controlled data at any dose above 2 mg daily.

Cardiac Structural Change

Chronic GH excess in acromegaly produces cardiomyopathy (disease of the heart muscle itself) with ventricular hypertrophy (thickening of the walls of the heart’s main pumping chambers), and one small imaging trial examined cardiac fat in this population. Nothing comparable has been observed at therapeutic doses over the durations studied, and the trial that examined cardiac steatosis (fat deposited within the heart muscle) was not powered for structural endpoints. The basis is disease-state extrapolation only.

Risk-Modifying Factors

Baseline IGF-1 relative to age: The clearest single modifier of risk. Trials excluded participants whose IGF-1 z-score (a statistic expressing how many standard deviations a value sits above or below the average for a person’s age and sex) exceeded 2.0, and starting near the top of the reference range means a standard dose pushes exposure into the range where joint symptoms, edema, and the theoretical neoplasia concern all concentrate. Low baseline IGF-1 widens the safety margin.
Baseline glucose control: HbA1c above 8% was an exclusion in the efficacy trials, so people with poorly controlled diabetes are largely unstudied; the exception is a 12-week randomized placebo-controlled trial in stable type 2 diabetes, which found no deterioration in insulin response or glycaemic control at 1 or 2 mg daily. Insulin resistance may still amplify the early glucose rise, and in readers with prediabetes the transient effect can be larger than the short-term trial data suggest.
Pituitary and hypothalamic integrity: Tesamorelin works only if there are functioning somatotrophs to stimulate. Prior hypophysectomy (surgical removal of the pituitary), hypopituitarism, pituitary tumor or surgery, cranial irradiation, or significant head trauma are absolute contraindications, both because the drug cannot work and because stimulating a residual pituitary adenoma is undesirable.
Active or recent malignancy: An absolute contraindication given the mitogenic properties of IGF-1. Trials excluded active or suspected malignancy within the preceding 24 months, excluding non-melanoma skin cancer, and required a normal mammogram or a prostate-specific antigen below 4 ng/mL before enrollment.
Sex-based differences: The safety database is heavily male, roughly 87% in the phase 3 program, so female-specific adverse event rates are imprecise. Women on oral estrogen achieve lower IGF-1 for a given dose, which shifts them toward under-dosing rather than over-exposure. Fluid-retention side effects are generally more prominent in women in the wider growth hormone literature.
Age: Older readers are more susceptible to fluid retention, joint symptoms, and carpal tunnel compression, and are more likely to have undetected malignancy that the mitogenic concern applies to. Countering this, the pituitary response declines with age, so the same dose typically produces a smaller IGF-1 excursion. The net effect is that the oldest readers need the same monitoring but often tolerate lower doses better.
Pre-existing conditions that change the risk calculus: Diabetic retinopathy, obstructive sleep apnea, established heart failure or unstable coronary disease, and adrenal insufficiency on cortisol replacement each interact with a specific mechanism above. Acute critical illness is a separate category: growth hormone increased mortality in intensive-care trials, so treatment is neither initiated nor continued through critical illness.
Genetic variants affecting the growth hormone axis: Carriers of the exon 3-deleted growth hormone receptor variant generate a larger IGF-1 response per unit of growth hormone and may reach the upper safety threshold at lower doses. This is inferred from the wider endocrine literature; it has not been tested in tesamorelin trials.

Key Interactions & Contraindications

Glucocorticoids (prednisone, hydrocortisone, cortisone acetate, dexamethasone) — caution, dose adjustment likely: Growth hormone inhibits 11β-HSD1, reducing conversion of inactive cortisone to active cortisol. Consequence: readers on cortisol replacement, and particularly on cortisone acetate, can become functionally under-replaced, with fatigue, low blood pressure, and in extreme cases adrenal crisis (a life-threatening collapse caused by too little cortisol). Mitigation: the replacement dose is reviewed before starting and reassessed at 4 to 6 weeks; upward adjustment is often required.
Glucose-lowering agents (metformin, sulfonylureas such as glipizide, insulin, GLP-1 receptor agonists such as semaglutide) — monitor: Growth hormone opposes insulin action, so glucose can rise in the first weeks. Consequence: loss of glycaemic control, or conversely hypoglycaemia if a co-prescribed agent is later reduced. Mitigation: fasting glucose is checked at 2 and 6 weeks and HbA1c at 3 months; initiation is held until HbA1c is below 8%.
Thyroid hormone replacement (levothyroxine, liothyronine) — monitor: Growth hormone increases peripheral conversion of thyroxine to the active triiodothyronine and can unmask marginal central hypothyroidism. Consequence: altered thyroid status in either direction. Mitigation: thyroid stimulating hormone and free thyroxine are measured at baseline and at 3 months.
Oral estrogens (combined oral contraceptives, oral estradiol) — caution, reduced effect: First-pass hepatic metabolism blunts the liver’s IGF-1 output in response to growth hormone. Consequence: a smaller IGF-1 rise and a smaller fat-loss effect at the same dose. Mitigation: where clinically appropriate, transdermal estrogen avoids the first-pass effect; otherwise a lower response is expected and measured rather than the dose escalated.
Other growth hormone secretagogues and growth hormone itself (sermorelin, CJC-1295, ipamorelin, GHRP-2, ibutamoren, somatropin) — avoid combination: All raise growth hormone and IGF-1 through the same or complementary routes. Consequence: additive or synergistic IGF-1 elevation above the physiological range, with the associated joint, fluid, and mitogenic concerns. Mitigation: stacking is avoided; when switching, a washout period and re-measurement of IGF-1 precede dose selection.
Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) — caution: Both tesamorelin and these agents promote sodium and fluid retention. Consequence: additive peripheral edema and, in susceptible readers, raised blood pressure. Mitigation: regular use is limited during the first months when fluid retention peaks, with ankle swelling and blood pressure monitored.
Over-the-counter melatonin and sedative sleep aids — minor, timing-relevant: Growth hormone release is coupled to slow-wave sleep, and bedtime dosing is standard. Consequence: no pharmacological interaction, but agents that fragment sleep architecture may blunt the endogenous pulse the drug amplifies. Mitigation: sleep aids that preserve deep sleep are preferred, with tesamorelin dosed close to sleep onset.
Supplements with additive growth hormone or IGF-1 effects (L-Arginine, L-Ornithine, glycine, gamma-aminobutyric acid, alpha-GPC, colostrum and deer antler velvet extracts) — caution: Amino acid secretagogues stimulate growth hormone release through partly independent routes, and colostrum and antler velvet products contain IGF-1 directly. Consequence: additive IGF-1 elevation, most relevant for readers already near the upper reference limit. Mitigation: these are separated or discontinued while titrating, and IGF-1 is measured rather than the contribution assumed trivial.
Supplements affecting blood glucose (berberine, chromium, alpha-lipoic acid, inositol) — monitor: These lower glucose and can partly offset the early rise on tesamorelin. Consequence: usually favorable, but the offset can mask a glucose effect that would otherwise prompt dose reassessment. Mitigation: the supplement regimen is kept stable across the first 3 months so glucose changes remain interpretable.
CYP3A4 substrates (simvastatin, ritonavir) — no action required: Dedicated crossover studies found effects on exposure within the standard no-effect range for simvastatin and only minor reductions for ritonavir. Consequence: none of clinical significance. Mitigation: no dose adjustment of either medication is needed.

Populations who should avoid tesamorelin:

Absolute contraindication — disruption of the hypothalamic-pituitary axis: hypophysectomy, hypopituitarism, pituitary tumor or pituitary surgery, cranial irradiation, or significant head trauma.
Absolute contraindication — active malignancy: any active or suspected malignancy, and any malignancy treated within the preceding 24 months other than non-melanoma skin cancer.
Absolute contraindication — hypersensitivity: known hypersensitivity to tesamorelin or to mannitol.
Absolute contraindication — pregnancy and breastfeeding: growth hormone excess is harmful in pregnancy and the compound has no safety data in lactation.
Avoid — poorly controlled diabetes: HbA1c above 8%, or established diabetes with active proliferative or severe non-proliferative retinopathy.
Avoid — IGF-1 already elevated: an IGF-1 z-score above 2.0 before treatment, which is the exclusion threshold used in the trials; the label sets a looser bar, advising that discontinuation be considered for persistent elevation above 3 standard deviation scores, particularly where the efficacy response is not robust.
Avoid — acute critical illness: open-heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure, based on excess mortality observed with growth hormone in intensive care.
Avoid — unstable cardiac disease: active or unstable coronary artery disease, chest pain suspicious for angina, or serious arrhythmia, which were exclusions in the current trials.
Avoid — under 18 years of age: no data exist and the drug acts on an axis that is still developmentally active.

Risk Mitigation Strategies

Cancer screening before the first dose: Age-appropriate screening (mammography within 2 years for women up to 74, prostate-specific antigen below 4 ng/mL for men up to 70, colorectal screening per age guidelines) is completed before starting and repeated annually. This directly addresses the theoretical promotion of occult neoplasia by IGF-1, which is the reason active malignancy is an absolute contraindication.
Baseline and interval IGF-1 with a discontinuation threshold: IGF-1 is measured with an age- and sex-adjusted z-score before starting, at 4 to 6 weeks, and every 3 months thereafter. The dose is reduced if the z-score exceeds 2.0, and treatment is discontinued if it remains above 2.0 after reduction. This is the single control point for joint symptoms, edema, and the mitogenic concern, all of which scale with IGF-1 exposure.
Sub-label starting dose with titration to the biomarker: Beginning at roughly half the labeled dose, for example 1 mg daily rather than 2 mg, for the first 4 weeks and increasing only if IGF-1 remains mid-range reduces the incidence of arthralgia, myalgia, and edema, which are dose-related and concentrate in the first month. The 1 mg dose was the dose used in the 20-week cognitive trial in older adults, so it is not an invented dose.
Early glucose surveillance in the first six weeks: Fasting glucose is checked at 2 weeks and 6 weeks, and HbA1c at 3 months, because the documented glucose rise is an early phenomenon that resolves by 6 months in most participants. This catches the minority in whom it does not resolve, which is the group the labeled diabetes warning is about, and deferring it to a routine annual panel misses that window.
Systematic injection site rotation: Injections are rotated across abdominal quadrants on a fixed cycle, avoiding the 5 cm around the navel and any scarred, bruised, or previously reactive skin. This addresses the most common adverse event and the leading cause of discontinuation; because benefit depends entirely on continued dosing, tolerability at the injection site is a benefit-preserving measure as much as a safety one.
Bedtime dosing with a fluid-retention check: Dosing 30 minutes before sleep aligns the pulse with the physiological nocturnal peak and moves the peak fluid effect into the sleeping hours. Daily weighing for the first month and a morning look at the ankles track the effect; a gain above 1 to 2 kg in the first weeks without dietary change signals fluid retention and warrants dose reduction rather than continuation.
Proactive adjustment of cortisol and thyroid replacement: For readers on cortisol replacement, the dose is reviewed before starting and reassessed at 4 to 6 weeks, since inhibition of 11β-HSD1 can leave them under-replaced. For readers on thyroid replacement, thyroid stimulating hormone and free thyroxine are measured at baseline and 3 months. Both prevent an avoidable endocrine decompensation rather than a drug side effect as such.
Avoiding stacks with other growth hormone secretagogues: Using tesamorelin alone rather than in the blends widely sold with ipamorelin, CJC-1295, or growth hormone-releasing peptide 2 keeps IGF-1 interpretable and avoids additive elevation above the physiological range. Stacking also makes it impossible to attribute either benefit or an adverse event to a specific agent.
Screening and monitoring for sleep-disordered breathing: For readers with snoring, witnessed apneas, or a raised neck circumference, a home sleep study is obtained before starting and repeated at 6 months. This addresses the plausible airway effect of fluid retention, and it doubles as a way to detect the opposite outcome, improvement from visceral and neck fat loss.
Predefined stopping rule at 6 months: What counts as response is defined in advance, typically a measured reduction in visceral fat area or hepatic fat fraction rather than scale weight, and treatment stops if it is not met. Roughly a third of trial participants were non-responders, and continuing exposes a reader to the full risk profile and cost for no measurable return.

Therapeutic Protocol

Standard approved protocol: The current United States product, Egrifta WR, is 1.28 mg injected subcutaneously once daily into the abdomen, reconstituted once weekly and stored at room temperature. Its predecessors were dosed at 2 mg daily: the original two-vial Egrifta, whose vials required refrigeration, and the single-vial Egrifta SV, whose vials are labeled for room-temperature storage; both required daily reconstitution and same-day use of the reconstituted solution. The dose figures differ because the formulations deliver different exposure, not because the target has changed.
Conventional endocrine approach: Endocrinologists and infectious-disease physicians treating the licensed indication dose to the label, evaluate response by imaging of visceral fat at 6 months, and discontinue non-responders. This approach was defined by the Theratechnologies phase 3 program and by the Massachusetts General Hospital metabolism group under Steven Grinspoon and Takara Stanley, whose trials established the liver-fat findings.
Longevity and peptide-clinic approach: Practitioners working outside the licensed indication typically use 1 to 2 mg daily, often 5 days on and 2 days off, and frequently titrate to a target IGF-1 in the upper half of the age-adjusted reference range rather than to a fixed dose. This framing is the one presented in Andrew Huberman’s peptide episode, which places tesamorelin alongside sermorelin as the growth hormone-releasing hormone options with human data, and it is contested by clinicians such as Peter Attia, whose position is that the growth hormone axis has repeatedly failed to deliver functional benefit in non-deficient adults. Neither approach has been tested head to head; they differ in what they consider the endpoint.
Best time of day: Bedtime, typically 30 minutes before sleep, on an empty stomach. Endogenous growth hormone is secreted in its largest pulse during early slow-wave sleep, so bedtime dosing is intended to amplify a physiological pulse rather than create an unphysiological one. The 20-week cognitive trial dosed 30 minutes before bedtime; the licensed product carries no time-of-day requirement.
Half-life and its practical consequence: The elimination half-life is roughly 26 to 38 minutes after subcutaneous injection. The drug is therefore long gone within a few hours, and what persists is the downstream IGF-1 elevation, which has a half-life measured in hours to days. This is why a short-acting peptide can be dosed once daily and why missing a single dose has little immediate consequence.
Single versus split dosing: Single daily dosing is correct and splitting is counterproductive. A second dose later in the day would create a growth hormone pulse out of phase with the circadian pattern, and no trial has used a split regimen. All efficacy and safety data derive from once-daily administration.
Injection technique: Subcutaneous into the abdomen, rotating quadrants each day, avoiding the 5 cm around the navel and any scarred, bruised, or reactive skin. Reconstituted solution is inspected for particles before use; Egrifta WR is stable at room temperature after reconstitution for the labeled interval, while the older formulations required same-day use.
Genetic considerations for dose selection: Carriers of the exon 3-deleted growth hormone receptor variant generate a larger IGF-1 rise per unit of growth hormone and may reach the target range at a lower dose; variants in the growth hormone-releasing hormone receptor gene blunt the response. Neither is routinely tested nor validated prospectively for tesamorelin, so measured IGF-1 remains the practical substitute for genotype-guided dosing.
Sex-based differences in dosing and response: Women on oral estrogen require a higher dose or a change to transdermal estrogen to achieve the same IGF-1 rise, because oral estrogen blunts hepatic IGF-1 generation. The trial population was roughly 87% male, so female dose-response data are thin, and titrating to measured IGF-1 rather than to a fixed dose matters more in women.
Age-related considerations: Trials have enrolled participants up to 87 years of age, and the ongoing functional trial enrolls 50 to 80 year olds. Older readers generally have lower baseline IGF-1 and more room to move, but a reduced pituitary response and greater susceptibility to fluid retention and joint symptoms; starting at 1 mg and titrating slowly is the more appropriate pattern above roughly age 70.
Baseline biomarkers that guide the protocol: IGF-1 with z-score determines both eligibility and target. Fasting glucose and HbA1c determine whether to start at all. Measured visceral fat area, by computed tomography, magnetic resonance imaging, or a dual-energy X-ray absorptiometry visceral fat estimate, defines whether there is enough of the target depot to justify treatment and provides the only meaningful response measure at 6 months.
Pre-existing conditions that alter the protocol: Fatty liver disease shifts the primary endpoint from visceral fat to hepatic fat fraction and extends the assessment window to 12 months, since the liver trial ran that long. Insulin resistance argues for a lower starting dose and tighter early glucose monitoring. Cortisol or thyroid replacement requires the dose reviews described under Risk Mitigation Strategies before the first injection.

Discontinuation & Cycling

Continuous rather than time-limited use: Tesamorelin is a maintenance therapy. The phase 3 extension showed that the visceral fat reduction was sustained through 52 weeks only in participants who continued, and regressed in those switched to placebo. There is no evidence for a durable remodeling effect that persists after stopping, so the practical choice is indefinite use or accepting return to baseline.
No withdrawal syndrome and no taper required: Because the mechanism is amplification of an endogenous pulsatile signal rather than replacement of a suppressed one, the pituitary is not downregulated by treatment and no rebound deficiency occurs. Growth hormone and IGF-1 return toward baseline over days to a few weeks after the last dose. Tapering is unnecessary; abrupt discontinuation is the norm in every trial that stopped treatment.
What does reverse, and how fast: Visceral fat returns over months rather than days, tracking the reversal of IGF-1. Fluid retention, joint symptoms, and injection site reactions resolve within days to two weeks. Whether the liver fat and fibrosis findings reverse on the same timescale has never been measured, since no trial followed participants after stopping the liver protocol.
Cycling is not required to maintain efficacy: No tachyphylaxis (progressive loss of response to a repeated dose) has been demonstrated over 52 weeks of continuous daily dosing; the IGF-1 response and the visceral fat effect were both maintained. Antibody formation in about half of participants did not attenuate the response either. The pharmacological case for scheduled breaks is therefore weak.
Reasons practitioners cycle anyway: Common off-label patterns are 5 days on and 2 days off, or 3 to 5 months on followed by a break. The stated rationales are limiting cumulative IGF-1 exposure for the longevity concern, allowing a washout to re-measure unstimulated IGF-1 and confirm the axis is intact, reducing cost, and giving injection sites time to recover. These are prudential rather than evidence-based, and 5-on-2-off has never been compared with daily dosing in a trial.
A defined exit at 6 months for non-responders: Roughly a third of trial participants did not achieve the 8% visceral fat reduction that defined response. Discontinuing at 6 months when the measured endpoint has not moved is the approach used in the licensed setting and avoids indefinite exposure without return.

Sourcing and Quality

Only one legitimate source exists: Tesamorelin is a prescription biologic-adjacent peptide manufactured by Theratechnologies and distributed in the United States as Egrifta WR through specialty pharmacies. In Canada it is marketed as Egrifta. There is no supplement-grade equivalent and no over-the-counter form.
Compounded tesamorelin sits outside the approved supply chain: Because a commercially available approved product exists, a compounding pharmacy generally may not produce what is essentially a copy of it. Compounded or telehealth-supplied tesamorelin therefore carries regulatory as well as quality uncertainty, and the identity, potency, and sterility assurances that accompany the approved product do not apply.
Research-grade peptide vials are not a substitute: Vials sold as research chemicals, including the tesamorelin, ipamorelin, and CJC-1295 blends widely marketed online, are not manufactured under pharmaceutical quality systems. Independent testing of the gray peptide market has repeatedly found under-dosing, incorrect peptides, bacterial endotoxin, and unlabeled excipients. Blends additionally make it impossible to attribute effect or adverse event to a single agent.
What to verify if a non-approved source is used at all: The meaningful check is a lot-specific certificate of analysis showing high-performance liquid chromatography purity of at least 98%, mass spectrometry confirmation of molecular identity matching the 44-amino-acid sequence with the trans-3-hexenoyl modification, and a bacterial endotoxin result. A certificate that is not lot-specific, or that reports purity without identity confirmation, says nothing about the vial in hand.
Formulation and excipient checks: The approved product is a lyophilized powder containing mannitol, with hydroxypropyl betadex added as a solubilizing excipient in the newer formulation. Egrifta WR is reconstituted with the supplied bacteriostatic water for injection, which is what permits a single vial to be used across seven days; the older Egrifta and Egrifta SV are reconstituted with sterile water and used the same day. Known hypersensitivity to tesamorelin or to any excipient in the product is disqualifying, since it is a labeled contraindication rather than a nuisance.
Storage and handling determine potency: Egrifta WR is stable at room temperature between 20 and 25 °C before and after reconstitution and is reconstituted once weekly; the older Egrifta SV is also stored at room temperature but required daily reconstitution and same-day use, while the original Egrifta required refrigerated vials. Peptides degrade with heat and agitation, so shipping conditions matter, and a vial that has arrived warm from an unverified supplier is of unknown potency.

Practical Considerations

Time to effect: IGF-1 rises within days and is measurable at 2 to 4 weeks. Visceral fat reduction is detectable by imaging at about 3 months and reaches most of its effect by 6 months, with further consolidation to 12 months. Liver fat changes were measured at 12 months in the trial that established them. Nothing about this compound produces a change visible on a scale in the first weeks, and scale weight is a poor tracker throughout because fat loss and lean gain partly offset.
Common pitfalls: Expecting loss of fat under the skin, which does not occur and is a feature of the mechanism rather than a failure of dosing. Judging response by body weight rather than by measured visceral or hepatic fat. Stopping before 3 months, before the effect is measurable. Stacking with ghrelin-receptor peptides, which confounds attribution and raises IGF-1 unpredictably. Skipping baseline IGF-1, which removes the only titration target. Injecting into the same site repeatedly, which produces the local reactions that most often end treatment. Assuming the trial safety profile transfers to a reader with poorly controlled blood sugar, a group the efficacy trials excluded and that the one dedicated diabetes safety trial enrolled only in stable, controlled form.
Regulatory status: Approved in the United States and Canada solely for reduction of excess abdominal fat in adults with HIV and lipodystrophy (the abnormal redistribution of body fat that can accompany long-term antiretroviral therapy). All longevity use is off-label. Tesamorelin is prohibited at all times in sport under the peptide hormones and growth factors class of the World Anti-Doping Agency list, so competitive athletes subject to testing are excluded regardless of prescription status.
Cost and accessibility: This is an exceptionally expensive intervention. United States list pricing has run in the range of several thousand dollars per month, placing annual cost in the tens of thousands, and insurers reimburse essentially only for the licensed indication. Because payers face a large cost differential between tesamorelin and the alternatives for abdominal fat, which are lifestyle intervention and inexpensive generic metabolic drugs, they have a systematic financial incentive to restrict access and to prefer cheaper comparators. That incentive is worth naming explicitly, because it is a potential source of structural bias in the same way manufacturer sponsorship is: coverage policy and the treatment guidelines that follow from it reflect cost as well as evidence, and the same cost differential shapes which comparisons get funded, since no payer or manufacturer has an interest in a head-to-head trial against a cheap generic. That runs alongside the opposite pull on the sponsored side, where the phase 3 evidence base reflects the manufacturer’s interest in a positive result. Off-label use is therefore almost entirely self-funded, and the indefinite duration of treatment compounds the cost.

Interaction with Foundational Habits

Sleep — direct and bidirectional: The largest endogenous growth hormone pulse occurs during early slow-wave sleep, and growth hormone-releasing hormone administration promotes slow-wave sleep in human sleep-laboratory work with the native hormone. Dosing 30 minutes before sleep is intended to exploit this alignment. The interaction runs in both directions: fragmented or short sleep blunts the endogenous pulse that tesamorelin amplifies, so poor sleep reduces the drug’s effect. Counterweight: fluid retention could plausibly worsen obstructive sleep apnea in susceptible readers, which is the practical reason to screen before starting.
Nutrition — indirect, potentiating or blunting depending on timing: Elevated insulin suppresses growth hormone release, so injecting shortly after a carbohydrate-containing meal blunts the pulse. The practical rule is to dose at least 2 hours after the last meal, which bedtime dosing usually satisfies. Adequate protein intake matters because the lean-mass gain requires substrate; the trials did not standardize diet, so the observed effect occurred against uncontrolled intake. There is no evidence that tesamorelin depletes any specific nutrient. Alcohol close to dosing is worth avoiding on the same logic as poor sleep, since it suppresses slow-wave sleep.
Exercise — potentiating, with no evidence of blunting: Resistance training and high-intensity intervals both raise endogenous growth hormone, and the mechanisms are complementary rather than competing. Unlike compounds that blunt training adaptation, nothing in tesamorelin’s mechanism interferes with hypertrophy signaling; if anything the raised IGF-1 acts on the same anabolic pathway. This combination is exactly what the ongoing TRIUMPH trial is testing, pairing tesamorelin with a home-based exercise programme in adults aged 50 to 80 with the primary endpoint of repeated chair stand time. Until it reports, the additive functional benefit is expected rather than demonstrated.
Stress management — indirect: Tesamorelin does not raise cortisol, which distinguishes it from ghrelin-receptor peptides such as growth hormone-releasing peptide 2 that stimulate cortisol and prolactin alongside growth hormone. It does lower effective tissue cortisol by inhibiting 11β-HSD1, which is the mechanism behind part of the visceral fat effect and the reason cortisol replacement doses may need adjustment. In the other direction, chronic psychological stress and the elevated cortisol that accompanies it suppress growth hormone pulse amplitude, so an unmanaged stress load works against the drug’s primary mechanism.

Monitoring Protocol & Defining Success

Baseline testing establishes both eligibility and the reference point against which response is judged; because roughly a third of trial participants were non-responders, a reader without a measured starting value has no way to distinguish response from its absence. The baseline work-up before the first injection comprises the full laboratory panel below, plus a quantitative measure of the target depot: visceral fat area by computed tomography or magnetic resonance imaging, or a dual-energy X-ray absorptiometry visceral fat estimate, with hepatic fat fraction by magnetic resonance imaging or a controlled attenuation parameter reading if fatty liver is the reason for treatment. It also includes age-appropriate cancer screening and, in women of childbearing potential, a pregnancy test.

Ongoing monitoring follows a front-loaded cadence: IGF-1 and fasting glucose at 2 and 6 weeks, then IGF-1, glucose, and HbA1c every 3 months; lipids and liver enzymes at 6 months and then every 6 to 12 months; repeat visceral fat imaging at 6 months and hepatic fat imaging at 12 months; thyroid function at baseline and 3 months; and cancer screening annually.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
IGF-1 (insulin-like growth factor 1)	Mid to upper-middle of the age- and sex-adjusted range; z-score between 0 and +1.5	The titration target and the proof the drug is working	Conventional labs report only “within range”, which spans a threefold spread, so the z-score is the informative form. Discontinuation applies if the z-score stays above 2.0. Non-fasting; drawn at a consistent time as levels are stable across the day
Fasting glucose	75-85 mg/dL (4.2-4.7 mmol/L)	Detects the early insulin-antagonist effect of growth hormone	Conventional cut-off for concern is 100 mg/dL, which is far too late here. Checked at 2 and 6 weeks specifically; a rise of about 7 mg/dL at 2 weeks is expected and usually resolves. 10-12 hour fast
HbA1c (glycated haemoglobin)	4.8-5.3%	Confirms the early glucose rise did not become persistent	Conventional threshold for prediabetes is 5.7%. Treatment is not started above 8.0%. Falsely low with anaemia or short red cell lifespan; paired with fasting insulin
Fasting insulin and HOMA-IR	Insulin below 5 µIU/mL; HOMA-IR below 1.0	Detects loss of insulin sensitivity before glucose moves	HOMA-IR is the homeostatic model assessment of insulin resistance, a calculation combining fasting glucose and insulin. Conventional laboratory reference for fasting insulin extends to roughly 25 µIU/mL, five times the functional target, so a “normal” result carries no information here. More sensitive than glucose to the growth hormone effect. Requires the same fasting draw as glucose; calculated rather than ordered separately
ALT	Below 25 U/L in men, below 20 U/L in women	Tracks the liver-fat benefit	ALT is alanine aminotransferase, a liver enzyme. Conventional upper limits near 40-55 U/L conceal meaningful fatty liver. Paired with AST (aspartate aminotransferase) and GGT (gamma-glutamyl transferase); a fall is expected if hepatic fat responds
Triglycerides	Below 80 mg/dL (0.9 mmol/L)	The lipid fraction most responsive to visceral fat loss	Conventional threshold is 150 mg/dL. 12-hour fast, no alcohol for 48 hours; paired with the triglyceride-to-HDL ratio, target below 1.5 in mg/dL units
hs-CRP	Below 0.5 mg/L	Tracks the inflammatory component of visceral fat	hs-CRP is high-sensitivity C-reactive protein, a sensitive marker of systemic inflammation. Conventional “low risk” is below 1.0 mg/L. Invalid within 2 weeks of infection, injury, or hard training; a single high value is repeated rather than interpreted
TSH with free T4	TSH 0.5-2.0 mIU/L with free T4 in the upper half of range	Growth hormone alters thyroid hormone conversion and can unmask marginal deficiency	TSH is thyroid stimulating hormone and T4 is thyroxine. The conventional reference range runs to about 4.5 mIU/L, so a value the laboratory flags as normal can still sit well outside the functional target. Morning draw before any thyroid medication; free T3 (triiodothyronine) is measured alongside if replacement is being adjusted
Visceral fat area	Reduction of at least 8% from baseline at 6 months	The primary definition of response used in the trials	By computed tomography or magnetic resonance imaging at the L4-L5 level, or a dual-energy X-ray absorptiometry visceral estimate. The same modality and the same centre are used for the repeat, as cross-method comparison is unreliable
Hepatic fat fraction	Below 5%, or a relative reduction of at least 30%	The endpoint if fatty liver is the reason for treatment	By magnetic resonance imaging proton density fat fraction, or a controlled attenuation parameter reading as a lower-cost proxy. Assessed at 12 months, not 6, since that is the interval the evidence covers
Waist circumference	Below 94 cm in men, below 80 cm in women	A zero-cost proxy that tracks the imaging endpoint	Measured at the iliac crest at end-expiration, same time of day, same person measuring. Roughly 1.6 cm of change is expected, so measurement error easily swamps the signal if technique varies

Qualitative markers worth tracking alongside the laboratory panel:

Morning ankle and hand swelling: the earliest and most reliable sign of the fluid retention that drives several other side effects.
Joint stiffness and aching, particularly in the hands and knees: typically appears in the first weeks and signals that the dose is above what is comfortable.
Numbness or tingling in the fingers, especially on waking: the practical warning sign for median nerve compression at the wrist.
Depth and continuity of sleep: both a possible benefit and, if it deteriorates with snoring, a warning about airway effects.
Waistband fit: often perceptible before imaging or the tape measure confirms it, and the change trial participants rated most highly.
Recovery between training sessions and daytime energy: the subjective outcomes most often cited in off-label use and the least supported by controlled data, which is precisely why a contemporaneous written record is more informative than recollection.
Injection site condition: persistent redness or nodules at rotated sites indicate a technique or product problem rather than an unavoidable effect.

Defining success at 6 months: a measured reduction of at least 8% in visceral fat area, or a relative hepatic fat reduction of at least 30% where fatty liver is the target, with IGF-1 in the upper-middle of the age-adjusted range, HbA1c unchanged from baseline, and no persistent edema or joint symptoms. Failure to meet the imaging endpoint is the trigger to stop, not to escalate the dose.

Emerging Research

Tesamorelin plus exercise for physical function in aging (TRIUMPH): The most directly relevant ongoing trial for a longevity-oriented reader, and the first to test whether the body-composition changes produce a functional gain. NCT06554717 is a phase 2, randomized, quadruple-blind trial of 100 adults aged 50 to 80 with HIV, at least one frailty criterion, and excess abdominal fat, comparing tesamorelin 1.28 mg daily plus a home-based exercise programme against placebo plus the same programme; the primary endpoint is change in repeated chair stand time at 24 weeks, with a 24-week off-treatment extension to test whether gains persist. Primary completion is estimated for June 2028. The protocol is published by Erlandson et al., 2026.
Tesamorelin for functional recovery after peripheral nerve injury: NCT03150511 is a Johns Hopkins phase 2, randomized, quadruple-blind trial of 36 participants with surgically repaired ulnar nerve lacerations, testing tesamorelin 2 mg daily against no treatment, with three-point chuck pinch strength at 12 months as the primary endpoint and estimated completion in December 2027. It is the only trial testing a regenerative rather than a metabolic endpoint, and a positive result would substantially broaden the mechanistic case.
Fatty liver disease outside the setting of HIV: NCT03375788 was a phase 2 trial of 51 participants testing tesamorelin against placebo for liver fat content and associated cardiovascular risk in fatty liver disease, completed in January 2025 with results posted to the registry. This is the single most important gap-filling study in the programme, because every published efficacy trial to date enrolled people with HIV, and generalization beyond that population currently rests on mechanism rather than data.
Evidence that weakens the cognitive case: Ellis et al., 2025 reported the 73-participant phase 2 trial registered as NCT02572323, which found no significant between-group difference in neurocognitive performance despite achieving the expected waist reduction, and no correlation between IGF-1 change and cognitive change. Read against the earlier positive trial in older adults, it makes the cognitive benefit look population- and design-dependent rather than robust, and it is the clearest published counterweight to the longevity framing.
Response-predictor biology: Work by Fourman et al., 2020 on hepatic transcriptomic signatures and by Fourman et al., 2021 on targeted proteomics is attempting to identify who responds and why, using liver biopsy and circulating protein data from the randomized liver trial. If a pretreatment signature emerges, it would address the most practical limitation of the compound, that roughly a third of users derive no measurable benefit while carrying the full cost and risk.
Areas of future research that could change current understanding: Whether visceral fat reduction translates into hard cardiovascular or mortality endpoints, which no trial has measured and which is the assumption the entire longevity case rests on. Whether sustained IGF-1 elevation over years is net favorable or unfavorable for lifespan, given that the comparative biology of reduced growth hormone signaling and cohort work such as Zhang et al., 2020 point the other way. Whether pairing tesamorelin with incretin-based weight loss preserves the lean mass those drugs cost, an obvious combination that remains entirely untested. And whether the fibrosis finding from the single liver trial of Stanley et al., 2019 replicates, since it is the only outcome in the literature that touches disease progression rather than an imaging surrogate.

Conclusion

Tesamorelin is a laboratory-made version of the brain signal that prompts the pituitary gland to release growth hormone. Because it works one step upstream rather than replacing the hormone directly, the body keeps its own pulsing rhythm and its own brakes. Its best-supported effect is a marked reduction in the deep fat packed around the abdominal organs, together with less fat in the liver and a modest gain in lean tissue. Those findings come from well-conducted placebo-controlled trials, but almost all of them enrolled people living with a chronic immune-system virus, and the pivotal ones were designed and paid for by the company that sells the drug. Whether the same fat loss produces fewer heart attacks, less liver scarring, or a longer life in otherwise healthy adults has not been measured.

The common unwanted effects are mild and predictable: irritation where it is injected, aching joints and muscles, swelling, and tingling in the hands. Blood sugar tends to drift upward early. The benefit fades once treatment stops, so it functions as an open-ended commitment rather than a course. The deepest uncertainty is a longevity one: lower lifetime growth signaling is linked with longer life in animals and in some human families, and this compound pushes that signal firmly in the other direction. The evidence supports the fat-loss claim clearly, and leaves the longevity question genuinely open.

Top - Benefits - Risks - Protocol

Tesamorelin for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Reduction of Deep Abdominal (Visceral) Fat

Reduction of Liver Fat

Increase in Lean Body Mass

Restoration of Insulin-Like Growth Factor 1 to the Upper Physiological Range

Medium 🟩 🟩

Improvement in Blood Lipids

Slowing of Liver Fibrosis Progression

Improvement in Muscle Quality and Reduction of Fat Infiltration in Muscle

Improvement in Self-Rated Body Composition and Body Image

Low 🟩

Cognitive Performance ⚠️ Conflicted

Reduction in Inflammatory Markers

Improvement in Mitochondrial Function

Speculative 🟨

Improved Sleep Depth

Accelerated Peripheral Nerve Regeneration

Preservation of Lean Mass Alongside Incretin-Based Weight Loss

Skin Quality and Recovery from Training

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Injection Site Reactions

Joint and Muscle Pain

Fluid Retention and Peripheral Edema

Early Rise in Blood Glucose ⚠️ Conflicted

Anti-Tesamorelin Antibody Formation

Medium 🟥 🟥

Loss of Benefit After Discontinuation

Paresthesia, Hypoesthesia, and Carpal Tunnel Syndrome

Hypersensitivity Reactions

Gastrointestinal Effects

Higher Discontinuation Rate on Treatment

Low 🟥

Theoretical Promotion of Occult Neoplasia

Worsening of Diabetic Retinopathy

Worsening of Sleep-Disordered Breathing

Suppression of Circulating Cortisol Through 11β-HSD1 Inhibition

Speculative 🟨

Unfavorable Long-Term Effect on Longevity from Sustained IGF-1 Elevation

Acromegaly-Like Soft Tissue Changes with Supraphysiological Off-Label Dosing

Cardiac Structural Change

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion